NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

With earnings season heating up this week, volatility reigned and we added shares to two of our model portfolio positions.

Stocks Under $10 Weekly Summary

As we prepare for earnings season, we used this week's broad market rally to halve one of our model portfolio positions.

Selling Shares on Strength

This name is trading higher for a seventh straight session, so we are booking some gains and lowering our rating to a Three.

Ask SUT

This week, David Peltier answers questions about portfolio management and healthcare stocks.

Locking In Some Gains

We are trimming this position on today's strength, but we expect the company's new products to continue to drive growth.

Stocks Under $10 Weekly Summary

We used the market's pullback this week to initiate a model portfolio position and add shares to two other names.

Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR

Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR

Cramer likes what Dominion Resources is doing while Waste Management is leading the disposal pack.

Cramer's 'Mad Money' Recap: The Winning Formula

Cramer's 'Mad Money' Recap: The Winning Formula

If a company's got growth, a great yield or is mostly domestic, the Fed has sent it an invitation to the market's rally, Cramer said.

Stocks Under $10 Weekly Summary

During this week's volatile trading, we exited one model portfolio position, trimmed another and added shares to one more.

Stocks Under $10 Weekly Summary

We used the headline-driven volatility this week to add to one model portfolio position and book some profits in another.

No Earnings Impact Yet

Although easy central bank policies are buoying the market, too many bad earnings announcements could start to matter.

Mad Money Uncovered: Orphan Drug Stocks

Mad Money Uncovered: Orphan Drug Stocks

Jim Cramer discusses NPS Pharma and its orphan drug franchise with Nicole Urken, Mad Money Research Director.

Cramer's Top Stock Picks: HTZ NPSP GLD

Cramer's Top Stock Picks: HTZ NPSP GLD

Cramer said it's time to get back into SPDR Gold Shares. Hertz is his favorite rental car and NPS is a great orphan drug company.

Cramer's 'Mad Money' Recap: Be an Informed Skeptic

Cramer's 'Mad Money' Recap: Be an Informed Skeptic

Believing the bears only keeps investors out of the bull markets.

Tuesday Trend Continues: Morning Movers

Tuesday Trend Continues: Morning Movers

U.S. stocks continue to trade higher on Tuesdays in 2013, as investors shift their focus away from Cyprus. Portfolio Manager David Peltier highlights early trading action.

Trimming on Strength

This pharmaceutical name is surging on a positive company announcement, making this a good time to lock in some gains.

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures point to slight gains on Wall Street; Electronic Arts CEO is resigning; Lululemon pulls certain yoga pants from stores; Adobe to report earnings.

NPS Pharma Buys Back Worldwide Rights To Short Bowel Syndrome Drug

NPS Pharma Buys Back Worldwide Rights To Short Bowel Syndrome Drug

Takeda decides Revestive is no longer a strategic asset.

NPS Pharmaceuticals And Takeda Revise Agreements And NPS Re-Gains Full Worldwide Rights To Teduglutide And Recombinant Human Parathyroid Hormone 1-84

NPS Pharmaceuticals And Takeda Revise Agreements And NPS Re-Gains Full Worldwide Rights To Teduglutide And Recombinant Human Parathyroid Hormone 1-84

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that NPS has re-gained the full worldwide rights to teduglutide (trade name in ...

Stocks Under $10 Weekly Summary

During a volatile, quadruple-witching options expiration week, we used rallies to book profits in two model portfolio names.

Stocks Under $10 Weekly Summary

As the Russell 2000 moved to new highs this week, we added shares to one model portfolio name and trimmed another one.

NPS Pharmaceuticals To Present At Barclays Capital Global Healthcare Conference

NPS Pharmaceuticals To Present At Barclays Capital Global Healthcare Conference

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Barclays Capital Global Healthcare Conference in Miami, Florida on Wednesday, March 13, 2013 at 11:15 a.

Stocks Under $10 Weekly Summary

We used the volatile trading action in the market this week to add to two of our model portfolio positions.

NPS Pharmaceuticals Observes Rare Disease Day 2013 And Celebrates 30th Anniversary Of National Organization For Rare Disorders

NPS Pharmaceuticals Observes Rare Disease Day 2013 And Celebrates 30th Anniversary Of National Organization For Rare Disorders

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, is joining the National Organization for Rare...

Stocks Under $10 Weekly Summary

This week, we took advantage of opportunities to put cash to work and add shares to two of our model portfolio positions.

NPS Pharmaceuticals Reports 2012 Financial Results And 2013 Guidance

NPS Pharmaceuticals Reports 2012 Financial Results And 2013 Guidance

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, reported its results for the fourth quarter...

NPS Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference

NPS Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 26, 2013 at 10:00 AM ET.

Stocks Under $10 Weekly Summary

We used this week's trading action to book some profits in one model portfolio name and add shares to three other positions.

Another Dose of Shares

We're adding to this promising pharmaceutical holding on broad-market weakness.

NPS Pharmaceuticals To Report 2012 Financial Results

NPS Pharmaceuticals To Report 2012 Financial Results

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its 2012 financial results on Thursday, February 21, 2013 at approximately 4:00 p.